Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures

References

• Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci. 1991;615:125–127.
   PubMedGoogle Scholar
• Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372(9639):657–668.
   PubMed Web of Science ®Google Scholar
• MacKeigan JP, Krueger DA. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex. Neuro Oncol. 2015;17(12):1550–1559.
   PubMed Web of Science ®Google Scholar
• Fraioli MF, Lecce M, Fraioli C, et al. Spinal giant cell tumor in tuberous sclerosis: case report and review of the literature. J Spinal Cord Med. 2013;36(2):157–160.
   PubMed Web of Science ®Google Scholar
• Koc G, Sugimoto S, Kuperman R, et al. Pancreatic tumors in children and young adults with tuberous sclerosis complex. Pediatr Radiol. 2017;47(1):39–45.
   PubMed Web of Science ®Google Scholar
• Saxena A, Sampson JR. Epilepsy in tuberous sclerosis: phenotypes, mechanisms, and treatments. Semin Neurol. 2015;35(3):269–276.
   PubMed Web of Science ®Google Scholar
• Curatolo P, Maria BL. Tuberous sclerosis. Handb Clin Neurol. 2013;111:323–331.
   PubMedGoogle Scholar
• Chu-Shore CJ, Major P, Camposano S, et al. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010;51(7):1236–1241.
   PubMed Web of Science ®Google Scholar
• Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49:243–254.
   PubMed Web of Science ®Google Scholar
• Krueger DA, Northrup H. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49:255–265.
   PubMed Web of Science ®Google Scholar
• Curatolo P, Jozwiak S, Nabbout R. Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations. Eur J Paediatr Neurol. 2012;16(6):582–586.
   PubMed Web of Science ®Google Scholar
• Moavero R, Cerminara C, Curatolo P. Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges. Childs Nerv Syst. 2010;26(11):1495–1504.
   PubMed Web of Science ®Google Scholar
• Curatolo P, Nabbout R, Lagae L, et al. Management of epilepsy associated with tuberous sclerosis complex: updated clinical recommendations. Eur J Paediatr Neurol. 2018;22(5):738–748.
   PubMed Web of Science ®Google Scholar
• Canevini MP, Kotulska-Jozwiak K, Curatolo P, et al. Current concepts on epilepsy management in tuberous sclerosis complex. Am J Med Genet C Semin Med Genet. 2018;178(3):299–308.
   PubMed Web of Science ®Google Scholar
• French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10056):2153–2163.
   PubMed Web of Science ®Google Scholar
• Prescribing Information for Afinitor®. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022334s6lbl.pdf
   Google Scholar
• Summary of Product Characteristics for Votubia. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022334s6lbl.pdf
   Google Scholar
• Curatolo P. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy. Pediatr Neurol. 2015;52:281–289.
   PubMed Web of Science ®Google Scholar
• Sirven JI, Noe K, Hoerth M, et al. Antiepileptic drugs 2012: recent advances and trends. Mayo Clin Proc. 2012;87(9):879–889.
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E. Mechanism of action of vigabatrin: correcting misperceptions. Acta Neurol Scand Suppl. 2011;124(192):5–15.
   Google Scholar
• Prescribing Information for Sabril®. Availbale from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020427s010s011s012,022006s011s012s013lbl.pdf
   Google Scholar
• Bombardieri R, Pinci M, Moavero R, et al. Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. Eur J Paediatr Neurol. 2010;14(2):146–149.
   PubMed Web of Science ®Google Scholar
• Friedman D, Bogner M, Parker-Menzer K, et al. Vigabatrin for partial-onset seizure treatment in patients with tuberous sclerosis complex. Epilepsy Behav. 2013;27(1):118–120.
   PubMed Web of Science ®Google Scholar
• Yum MS, Lee EH, Ko TS. Vigabatrin and mental retardation in tuberous sclerosis: infantile spasms versus focal seizures. J Child Neurol. 2013;28(3):308–313.
   PubMed Web of Science ®Google Scholar
• Origlieri C, Geddie B, Karwoski B, et al. Optical coherence tomography to monitor vigabatrin toxicity in children. J AAPOS. 2016;20(2):136–140.
   PubMed Web of Science ®Google Scholar
• Riikonen R, Rener-Primec Z, Carmant L, et al. Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study. Dev Med Child Neurol. 2015;57(1):60–67.
   PubMed Web of Science ®Google Scholar
• Greiner HM, Lynch ER, Fordyce S, et al. Vigabatrin for childhood partial-onset epilepsies. Pediatr Neurol. 2012;46(2):83–88.
   PubMed Web of Science ®Google Scholar
• Jennesson M, van Eeghen AM, Caruso PA, et al. Clobazam therapy of refractory epilepsy in tuberous sclerosis complex. Epilepsy Res. 2013;104(3):269–274.
   PubMed Web of Science ®Google Scholar
• Franz DN, Tudor C, Leonard J, et al. Lamotrigine therapy of epilepsy in tuberous sclerosis. Epilepsia. 2001;42(7):935–940.
   PubMed Web of Science ®Google Scholar
• Collins JJ, Tudor C, Leonard JM, et al. Levetiracetam as adjunctive antiepileptic therapy for patients with tuberous sclerosis complex: a retrospective open-label trial. J Child Neurol. 2006;21(1):53–57.
   PubMed Web of Science ®Google Scholar
• Madeo M, Kovacs AD, Pearce DA. The human synaptic vesicle protein, SV2A, functions as a galactose transporter in Saccharomyces cerevisiae. J Biol Chem. 2014;289(48):33066–33071.
   PubMed Web of Science ®Google Scholar
• Overwater IE, Bindels-de Heus K, Rietman AB, et al. Epilepsy in children with tuberous sclerosis complex: chance of remission and response to antiepileptic drugs. Epilepsia. 2015;56(8):1239–1245.
   PubMed Web of Science ®Google Scholar
• Zhang B, McDaniel SS, Rensing NR, et al. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. PLoS One. 2013;8(2):e57445.
   PubMed Web of Science ®Google Scholar
• McDaniel SS, Rensing NR, Thio LL, et al. The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway. Epilepsia. 2011;52(3):e7–e11.
   PubMed Web of Science ®Google Scholar
• Prescribing Information for Epidiolex®. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf
   Google Scholar
• Devinsky O, MarshE, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270–278.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. A randomized controlled trial of cannabidiol (GWP42003-P, CBD) for seizures in tuberous sclerosis complex (GWPCARE6). NCT02544763. Available from: https://clinicaltrials.gov/ct2/show/NCT02544763
   Google Scholar
• Hess EJ, Moody KA, Geffrey AL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 2016;57(10):1617–1624.
   PubMed Web of Science ®Google Scholar
• Ryther RC, Wong M. Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy. Curr Neurol Neurosci Rep. 2012;12(4):410–418.
   PubMed Web of Science ®Google Scholar
• Wong M, Roper SN. Genetic animal models of malformations of cortical development and epilepsy. J Neurosci Methods. 2016;260:73–82.
   PubMed Web of Science ®Google Scholar
• Meikle L, Pollizzi K, Egnor A, et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci. 2008;28(21):5422–5432.
   PubMed Web of Science ®Google Scholar
• Curatolo P, Moavero R. mTOR inhibitors as a new therapeutic option for epilepsy. Expert Rev Neurother. 2013;13(6):627–638.
   PubMed Web of Science ®Google Scholar
• Overwater IE, Reitman AB, Bindels-de Heus K, et al. Sirolimus for epilepsy in children with tuberous sclerosis complex: a randomized controlled trial. Neurology. 2016;87(10):1011–1018.
   PubMedGoogle Scholar
• Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43(2):83–95.
   PubMed Web of Science ®Google Scholar
• Combes FP, Baneyx G, Coello N, et al. Population pharmacokinetics-pharmacodynamics of oral everolimus in patients with seizures associated with tuberous sclerosis complex. J Pharmacokinet Pharmacodyn. Epub 2018 July 12;45:707–719.
   PubMed Web of Science ®Google Scholar
• Franz DN, Lawson JA, Yapici Z, et al. Everolimus dosing recommendations for tuberous sclerosis complex-associated refractory seizures. Epilepsia. 2018;59(6):1188–1197.
   PubMed Web of Science ®Google Scholar
• Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010;363(19):1801–1811.
   PubMed Web of Science ®Google Scholar
• Krueger D, Care M, Agricola K, et al. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology. 2013;80(6):574–580.
   PubMed Web of Science ®Google Scholar
• Franz DN, Agricola K, Mays M, et al. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis. Ann Neurol. 2015;78(6):929–938.
   PubMed Web of Science ®Google Scholar
• Krueger DA, Wilfong AA, Holland-Bouley K, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol. 2013;74(5):679–687.
   PubMed Web of Science ®Google Scholar
• Krueger DA, Wilfong AA, Mays M, et al. Long-term treatment of epilepsy with everolimus in tuberous sclerosis. Neurology. 2016;87(23):2408–2415.
   PubMed Web of Science ®Google Scholar
• Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125–132.
   PubMed Web of Science ®Google Scholar
• Mizuguchi M, Ikeda H, Kagitani-Shimono K, et al. Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan. Brain Dev. 2018;41(1):1–10.
   PubMed Web of Science ®Google Scholar
• Franz DN, Lawson JA, Yapici Z, et al. Everolimus for treatment-refractory seizures in TSC. Extension of a randomized controlled trial. Neurol Clin Pract. 2018;8(5):412–420.
   PubMedGoogle Scholar
• Curatolo P, Franz DN, Lawson JA, et al. Adjunctive everolimus for children and adolescents with treatment-refractory seizures associated with tuberous sclerosis complex: post-hoc analysis of the phase 3 EXIST-3 trial. Lancet Child Adolesc Health. 2018;2(7):495–504.
   PubMedGoogle Scholar
• Peters J, Prohl A, Hodgeman R et al. Time to vigabatrin”: cognitive outcome in tuberous sclerosis comples is related to timely imitiation of vigabatrin specifically. Presented at the American Epilepsy Society 69th Annual Meeting; 2015 Dec 4–8; Philadelphia, Pennsylvania. Abst. 3.193.
   Google Scholar
• Zak S, Mokhallati N, Su W, et al. Lymphangioleiomyomatosis mortality in patients with tuberous sclerosis complex. Ann Am Thorac Soc. 2019 Apr;16(4):509-512.
   Web of Science ®Google Scholar
• Yapici Z, Fan PC, Lawson JA et al. Long-term safety, roll-over study of adjunctive everolimus in patients with tuberous sclerosis complex (TSC)-associated treatment-refractory seizures who continue to benefit from everolimus treatment after completion of EXIST-3. Poster presented at 13th European Congress of Epileptology; 2018 Aug 26–30; Vienna, Austria.
   Google Scholar
• Pharmaceuticals GW. GW pharmaceuticals reports positive phase 3 pivotal trial results for EPIDIOLEX® (cannabidiol) oral solution in patients with seizures associated with tuberous sclerosis complex. [cited 2019 May 8]. Available from: http://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-reports-positive-phase-3-pivotal-trial
   Google Scholar
• Novartis Pharmaceuticals Corporation. Novartis drug Afinitor Disperz® receives FDA approval to treat TSC-associated partial-onset seizures. [cited 2019 Feb 22]. Available from: https://www.pharma.us.novartis.com/print/15441
   Google Scholar
• Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817–824.
   PubMed Web of Science ®Google Scholar
• Franz DN, Belousova E, Sparagana S, et al. Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study. PLoS One. 2016;11(6):e0158476.
   PubMed Web of Science ®Google Scholar
• Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus long-term use in patients with tuberous sclerosis complex: four-year update of the EXIST-2 study. PLoS One. 2017;12(8):e0180939.
   PubMed Web of Science ®Google Scholar
• Dahdah N. Everolimus for the treatment of tuberous sclerosis complex-related cardiac rhabdomyomas in pediatric patients. J Pediatr. 2017;190:21–26 e7.
   PubMed Web of Science ®Google Scholar
• Schmid GL, Kassner F, Uhlig HH, et al. Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies. Pediatr Res. 2014;75(4):527–534.
   PubMed Web of Science ®Google Scholar
• Zak M, Ledbetter M, Maertens P. Infantile Lhermitte-Duclos disease treated successfully with rapamycin. J Child Neurol. 2017;32(3):322–326.
   PubMed Web of Science ®Google Scholar
• Schmidt LS, Linehan WM. Clinical features, genetics and potential therapeutic approaches for Birt-Hogg-Dube syndrome. Expert Opin Orphan Drugs. 2015;3(1):15–29.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Yao M, Sano F, et al. A case of metastatic renal cell carcinoma associated with Birt-Hogg-Dube syndrome treated with molecular-targeting agents. Hinyokika Kiyo. 2013;59(8):503–506.
   PubMedGoogle Scholar
• Marsh DJ, Trahair TN, Martin JL, et al. Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol. 2008;5(6):357–361.
   PubMedGoogle Scholar
• Capal JK, Bernardino-Cuesta B, Horn PS, et al. Influence of seizures on early development in tuberous sclerosis complex. Epilepsy Behav. 2017;70(Pt A):245–252.
   PubMedGoogle Scholar
• O’Callaghan FJ, Edwards SW, Alber FD, et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol. 2017;16(1):33–42.
   PubMed Web of Science ®Google Scholar
• Franz DN, Capal JK. mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders. Orphanet J Rare Dis. 2017;12(1):51.
   PubMedGoogle Scholar
• Weckhuysen S, Marsan E, Lambrecq V, et al. Involvement of GATOR complex genes in familial focal epilepsies and focal cortical dysplasia. Epilepsia. 2016;57(6):994–1003.
   PubMed Web of Science ®Google Scholar
• Moller RS, Weckhuysen S, Chipaux M, et al. Germline and somatic mutations in the MTOR gene in focal cortical dysplasia and epilepsy. Neurol Genet. 2016;2(6):e118.
   PubMed Web of Science ®Google Scholar
• Chassoux F, Landre E, Mellerio C, et al. Type II focal cortical dysplasia: electroclinical phenotype and surgical outcome related to imaging. Epilepsia. 2012;53(2):349–358.
   PubMed Web of Science ®Google Scholar
• Pitkänen A, Buckmaster P, Galanopoulou AS, et al. Models of seizures and epilepsy. Cambridge (MA), USA: Academic Press; 2017.
   Google Scholar